Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mobile PET Systems Inc. (MBPT) -- Ignore unavailable to you. Want to Upgrade?

To: Bull Dog who wrote (3)	3/31/1999 7:40:00 AM
From: Mark IV	Respond to of 10

UCLA P.E.T. Leader Joins MBPT Medical Advisory Board SAN DIEGO--(BW HealthWire)--March 25, 1999--Mobile P.E.T. Systems Inc. (OTCBB:MBPT - news), the first provider of mobile state-of-the-art Positron Emission Tomography (P.E.T.) technology, announced that Johannes Czernin, M.D., has accepted a position on the company's Medical Advisory Board. Czernin is Director of Nuclear Medicine and Positron Emission Tomography at the University of California, Los Angeles Medical School. MBPT integrates state-of-the-art P.E.T. imaging equipment and the technician necessary to provide diagnostic P.E.T. services into a specially designed mobile coach. The service is made available to medical institutions on a negotiated contractual basis. ''The addition of Dr. Czernin to our Medical Advisory Board adds further strength and expertise to the company,'' said David C. Frakes, M.D., F.R.C.P.C., Medical Advisory Board Chairman for MBPT. ''Dr. Czernin is widely published in cardiovascular P.E.T. research, and is a well-known expert in the field both in the USA and in Europe. We are delighted to add his experience to our team.'' About Johannes Czernin, M.D. Czernin serves as Associate Professor in the Department of Molecular and Medical Pharmacology as well as Associate Professor in the Department of Medicine at UCLA's School of Medicine. Czernin earned his medical degree from the University of Vienna Medical School. He is Board Certified in both internal medicine (Austria) and nuclear medicine (U.S.). Latest Research Demonstrates P.E.T.'s Advantages ''Studies we have conducted at UCLA with lung cancer patients show that, in conjunction with computed axial tomography (CT), P.E.T. is more cost-effective than CT alone,'' Czernin said. ''P.E.T. can result in avoiding unnecessary surgery, or in some cases, can indicate surgery for patients whose conditions had been suggested by CT alone to be inoperable.'' In interviewing over 100 physicians, Czernin's team found that the use of P.E.T. had led to significant changes in the staging of disease, and that the P.E.T. scans had actually resulted in a change in patient management in over 25 percent of cases. ''The bottom line is that the addition of P.E.T. resulted in patients getting better, and more cost-effective care.'' White House Announces P.E.T. Inventor As Winner of Fermi Award Last month, the White House named Michael E. Phelps, Ph.D., inventor of P.E.T. and Chairman of the Department of Molecular and Medical Pharmacology at UCLA as a winner of the prestigious Enrico Fermi Award, given for a lifetime of achievement in the field of nuclear energy. The Fermi Award is the oldest science award in the U.S. An Idea Whose Time Has Come ''The recent White House award exemplifies the fact that P.E.T. is finally being recognized for the benefits and power that it can bring to society,'' Czernin said. ''The Fermi Award not only underscores Dr. Phelps' personal accomplishments, it recognizes P.E.T. as an invaluable clinical tool.'' Czernin went on to state that Phelps also supports the concept of mobile P.E.T. wholeheartedly. ''Mobile P.E.T. technology is an idea whose time has come. It is the first step to bringing P.E.T. into the community in a very cost-effective fashion.'' Insurers Cover Scans -- Mobile P.E.T. Provides Access MBPT's service brings advanced P.E.T. imaging technology to hospitals that may not have sufficient patient volumes to purchase their own equipment. The contract arrangement safeguards hospitals from financial exposure and technological obsolescence. As its clinical value continues to be recognized, P.E.T. is gaining wider reimbursement to make it even more accessible. Some 70-percent of all insurance companies now pay for P.E.T., and this month, the Health Care Finance Administration (HCFA) announced expanded Medicare reimbursement to include P.E.T. scanning in the diagnosis and management of some of the most common cancers: colon and rectal cancers, lymphomas, plus malignant melanoma (the leading cause of death from skin cancer), as well as the previously approved lung cancer P.E.T. indications. About P.E.T. Technology Positron Emission Tomography (P.E.T.) is an advanced imaging technique that assists in the diagnosis and management of numerous diseases. P.E.T. allows the physician to examine the whole patient at once, by producing images of the body based on functional rather than anatomic characteristics. These images show body metabolism and other functions rather than simply the gross anatomy and structure revealed by conventional x-rays, CT or MRI scans. Whole-body P.E.T. imaging uncovers abnormalities that might otherwise go undetected. Physicians may then apply the most appropriate treatment for the detected disease. For example, P.E.T. can detect tumors unseen by other imaging techniques, or detect Alzheimer's Disease one to two years before the diagnosis would be made clinically. The unique ''shared service'' provided by MBPT allows hospitals the ability to offer P.E.T. imaging services to their own communities through their own medical staffs, and in a cost-effective manner. Patients who previously might have to travel hundreds of miles for a P.E.T. scan can now be studied at their local hospital. To learn more about MBPT, visit the company's web site at www.mobilepet.com. Certain information included in this communication (as well as information included in oral statements or other written statements made or to be made by Mobile P.E.T. Systems Inc.) contains statements that are forward-looking, such as statements relating to the future anticipated direction of the health care industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. These forward statements are subject to a number of known and unknown risks and uncertainties that could cause actual operations or results to differ materially from those anticipated. For more information on the Enrico Fermi Award: pub.whitehouse.gov 2/18/11.text.1. Click on White House Electronic Publications to access document and type in pdi://oma.eop.gov.us/1999/2/18/11.text.1 in the PDI Document-ID Section. Contact: Mobile P.E.T. Systems Inc. Paul Crowe, 619/226-6738 admin@mobilepet.com

To: Bull Dog who wrote (3)	3/31/1999 8:05:00 AM
From: Mark IV	Respond to of 10

Hi Bull Dog! I think the management team wasn't involved in any other public companies. But looking at the latest press releases the management must have been involved in the medical industry for quite some time. MBPT's advisory board is just amazing! I think this is a great company and as soon as they'll get the first truck the "stock-ride" up the hill will start ... Mark

To: Bull Dog who wrote (3)	4/10/1999 12:37:00 AM
From: Mark IV	Read Replies (1) \| Respond to of 10

MBPT Appoints a New Chief Financial Officer and a Director of Corporate Development SAN DIEGO--(BW HealthWire)--April 8, 1999--Mobile P.E.T. Systems Inc. (OTCBB:MBPT - news), the first company to provide mobile Positron Emission Tomography (P.E.T.), is pleased to announce the appointment of Thomas G. Brown as the company's new chief financial officer. Brown is a graduate of the University of Southern California, with a BS degree in Business Administration and an MBA, and is a Chartered Financial Analyst (CFA). Brown is a member of the Institute of Chartered Financial Analysts, the Orange County Society of Institutional Managers, and the Association for Corporate Growth. About Thomas G. Brown Brown has more than 30 years of experience in the analysis, structuring, investing and procurement of capital for private and public companies. During the past several years, he has concentrated on sourcing capital for leveraged transactions and growth capital for private and public companies. New Director of Corporate Development MBPT also announced that Leonard MacMillan has joined the MBPT team as Director of Corporate Development. MacMillan will ensure steady, personal communication between the company's senior management and key industry contacts such as analysts, brokers, fund managers, plus institutional and private investors. About Leonard MacMillan MacMillan will be closely involved with the company's CEO and CFO, using his 25 years of experience marketing public companies effectively and efficiently worldwide. MacMillan brings to MBPT a commitment to creating a broad-based support from the financial and investment communities, and ensuring that shareholders and potential investors have access to timely informational in a friendly, professional manner. About MBPT MBPT provides hospitals with access to state-of-the-art P.E.T. imaging equipment and the trained technician to provide diagnostic P.E.T. services -- integrated into a specially designed mobile coach. The company's contract arrangement safeguards hospitals from financial exposure and technological obsolescence. Over 70-percent of all insurance companies pay for P.E.T. Last month, Medicare expanded reimbursement to include P.E.T. scanning in the diagnosis and management of some of the most common cancers. This expanded reimbursement, coupled with the rapid expansion of mobile P.E.T. services through MBPT, will increase access for thousands of patients. About P.E.T. P.E.T. is an advanced imaging technique that assists in the diagnosis and management of numerous diseases. P.E.T. allows the physician to examine the whole patient at once, by producing images of the body based on functional rather than anatomic characteristics. These images show body metabolism and other functions rather than simply the gross anatomy and structure revealed by conventional x-rays, CT or MRI scans. Whole-body P.E.T. imaging uncovers abnormalities that might otherwise go undetected. Physicians may then apply the most appropriate treatment for the detected disease. For example, P.E.T. can detect tumors unseen by other imaging techniques, or detect Alzheimer's Disease one to two years before the diagnosis would be made clinically. The unique ''shared service'' provided by MBPT allows hospitals the ability to offer P.E.T. imaging services to their own communities through their own medical staffs, and in a cost-effective manner. Patients who once had to travel hundreds of miles for a P.E.T. scan can now be studied at their local hospital. To learn more about MBPT, visit our Web site at www.mobilepet.com. Certain information included in this communication (as well as information included in oral statements or other written statements made or to be made by Mobile P.E.T. Systems Inc.) contains statements that are forward-looking, such as statements relating to the future anticipated direction of the health-care industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. These forward statements are subject to a number of known and unknown risks and uncertainties that could cause actual operations or results to differ materially from those anticipated. Contact: Mobile P.E.T. Systems Inc. Leonard MacMillan, 619/226-6738 admin@mobilepet.com